#NPRreads: Get Below The Surface This Weekend With These 3 Stories
Correspondents, editors and producers from NPR's newsroom share the pieces that have kept them reading, using the #NPRreads hashtag.
U.S.
As Our Jobs Are Automated, Some Say We'll Need A Guaranteed Basic Income
How will the economy provide economic opportunities if employers need fewer workers in the future? A growing number of people in Silicon Valley are saying the only realistic answer is a basic income.
Ted Cruz Endorses Donald Trump
Ted Cruz has reversed a long held position and endorsed Donald Trump for president. Scott Simon discusses what the endorsement means with Ron Elving, senior editor for NPR's Washington Desk.
How Will Bernie Sanders Supporters Vote?
Scott Simon speaks to Jeff Weaver, former campaign manager for Bernie Sanders about how the Bernie coalition will vote in November.
The Latest On New Jersey 'Bridgegate' Trial
All week, jurors in New Jersey have been hearing about how aides to Gov. Chris Christie orchestrated the closure of lanes on the George Washington Bridge in 2013. We'll catch up on the trial.
The Week In Sports
Football season has begun and there's plenty to talk about. Howard Bryant of ESPN.com talks to NPR's Scott Simon about the week in sports.
The American Diplomat Who Helped Bring An End To Colombia's War
An American negotiator played a key role in helping Colombia end it's half-century war between the government and the FARC guerrillas. Here's how he did it.
How Law Enforcement Working With Regulatory Agencies To Thwart Terrorist Use Of IEDs
It's relatively simple for criminals to buy pressure cookers and turn them into deadly devices. William Flynn, formerly of the Department of Homeland Security, talks to NPR's Scott Simon.
Political Trends In Medicine: How Does Election Season Affect Our Health?
NPR's Scott Simon talks politics with Sally Satel, a clinical psychiatrist and medical policy expert. She follows political trends in medicine.
Controversy Continues Over Muscular Dystrophy Drug, Despite FDA Approval
The Food and Drug Administration approved a muscular dystrophy drug despite deeply flawed evidence. Was the decision a dangerous precedent or flexible pragmatism reflecting patients' values?